The latest results on the use of convalescent plasma in Covid-19 are now out from the RECOVERY trial as a pre-print. As you know we have already covered the trial […]
JC: Convalescent plasma (still) does not work in COVID-19. St Emlyn’s Read More
This week the RECOVERY trial has released the first results from the Colchicine arm of the trial. We await the pre-print and the peer reviewed paper, but we are already
Colchicine does not improve mortality in COVID19. St Emlyn’s Read More
It’s very rare we produce three instalments on one particular drug for one particular condition, and certainly not within such a short time frame. However, tocilizumab has been worth it.
Tocilizumabulous? A special offer on IL-6 with Tocilizumab. Read More
In arguably the most important therapeutic news of the pandemic since Dexamethasone, the RECOVERY trial investigators have revealed the initial results on the Tocilizumab arm of the trial showing a
JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s Read More
Hot on the heels of a terrific pun and blog post about the use of Tocilizumab, capturing all the intrigue, hope and caution with the potential use of this novel therapeutic
Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s Read More
We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine
JC: Lopinavir/Ritonavir in the treatment of COVID-19 Read More
As we near the end of 2020, it is worth taking a moment to reflect on what a year it has been. At the beginning of the year we were
JC: Azithromycin in patients hospitalised with COVID-19 Read More
A defining feature of the COVID-19 pandemic has been the wide spectrum of clinical presentations, ranging from asymptomatic viremia to life-threatening illness.1 Factors such as advancing age and co-morbid status have
The Emerging Evidence for a Genetic Susceptibility to Severe Covid-19. St Emlyn’s Read More
